Author | Gomes, L. R. | |
Author | Martins, Y. C. | |
Author | Cruz, M. F. Ferreira da | |
Author | Daniel-Ribeiro, Cláudio Tadeu | |
Access date | 2015-06-08T14:01:51Z | |
Available date | 2015-06-08T14:01:51Z | |
Document date | 2014 | pt_BR |
Citation | GOMES, L. R. et al. Autoimmunity, phospholipid-reacting antibodies and malaria immunity. Lupus, v.23, n.12, p.1295-1298, oct. 2014. | pt_BR |
ISSN | 1477-0962 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/10693 | |
Language | eng | pt_BR |
Publisher | SAGE Publications | pt_BR |
Rights | open access | pt_BR |
Title | Autoimmunity, phospholipid-reacting antibodies and malaria immunity | pt_BR |
Type | Article | pt_BR |
DOI | 10.1177/0961203314546021 | pt_BR |
Abstract | Several questions regarding the production and functioning of autoantibodies (AAb) during malaria infection remain open. Here we provide an overview of studies conducted in our laboratory that shed some light on the questions of whether antiphospholipid antibodies (aPL) and other AAb associated with autoimmune diseases (AID) can recognize Plasmodia antigens and exert anti-parasite activity; and whether anti-parasite phospholipid antibodies, produced in response to malaria, can inhibit phospholipid-induced inflammatory responses and protect against the pathogenesis of severe malaria. Our work showed that sera from patients with AID containing AAb against dsDNA, ssDNA, nuclear antigens (ANA), actin, cardiolipin (aCL) and erythrocyte membrane antigens recognize plasmodial antigens and can, similarly to monoclonal AAb of several specificities including phospholipid, inhibit the growth of P. falciparum in vitro. However, we did not detect a relationship between the presence of anti-glycosylphosphatidylinositol (GPI) antibodies in the serum and asymptomatic malaria infection, although we did register a relationship between these antibodies and parasitemia levels in infected individuals. Taken together, these results indicate that autoimmune responses mediated by AAb of different specificities, including phospholipid, may have anti-plasmodial activity and protect against malaria, although it is not clear whether anti-parasite phospholipid antibodies can mediate the same effect. The potential effect of anti-parasite phospholipid antibodies in malarious patients that are prone to the development of systemic lupus erythematosus or antiphospholipid syndrome, as well as the (possibly protective?) role of the (pathogenic) aPL on the malaria symptomatology and severity in these individuals, remain open questions. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa em Malária. Rio de Janeiro, RJ, Brasil / Ministério da Saúde. Secretaria de Vigilância em Saúde. Brasília, DF, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa em Malária. Rio de Janeiro, RJ, Brasil / Ministério da Saúde. Secretaria de Vigilância em Saúde. Brasília, DF, Brasil / Albert Einstein College of Medicine. Department of Pathology. NewYork, USA. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa em Malária. Rio de Janeiro, RJ, Brasil / Ministério da Saúde. Secretaria de Vigilância em Saúde. Brasília, DF, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa em Malária. Rio de Janeiro, RJ, Brasil / Ministério da Saúde. Secretaria de Vigilância em Saúde. Brasília, DF, Brasil. | pt_BR |
Subject | Systemic lupus erythematosus | pt_BR |
Subject | anti-DNA antibodies | pt_BR |
Subject | Malaria | pt_BR |
Subject | Antiphospholipid syndrome | pt_BR |
DeCS | Anticorpos Antinucleares | pt_BR |
DeCS | Lúpus Eritematoso Sistêmico | pt_BR |
DeCS | Síndrome Antifosfolipídica | pt_BR |
DeCS | Malária | pt_BR |